1. Watt NT, Whitehouse IJ, Hooper NM: The role of zinc in Alzheimer's disease.Int J Alzheimers Dis 2010, 2011:971021.
2. Dong J, Robertson JD, Markesbery WR, Lovell MA: Serum zinc in the progression of Alzheimer's disease.J Alzheimers Dis 2008, 15:443-450.
3. Religa D, Strozyk D, Cherny RA, Volitakis I, Haroutunian V, Winblad B, Naslund J, Bush AI: Elevated cortical zinc in Alzheimer disease.Neurology 2006, 67:69-75.
4. Brewer GJ, Kanzer SH, Zimmerman EA, Molho ES, Celmins DF, Heckman SM, Dick R: Subclinical zinc deficiency in Alzheimer's disease and Parkinson's disease.Am J Alzheimers Dis Other Demen 2010, 25:572-575.
5. Baum L, Chan IH, Cheung SK, Goggins WB, Mok V, Lam L, Leung V, Hui E, Ng C, Woo J, et al: Serum zinc is decreased in Alzheimer's disease and serum arsenic correlates positively with cognitive ability.Biometals 2010, 23:173-179.
6. Li DD, Zhang W, Wang ZY, Zhao P: Serum Copper, Zinc, and Iron Levels in Patients with Alzheimer's Disease: A Meta-Analysis of Case-Control Studies.Front Aging Neurosci 2017, 9:300.
7. Wang ZX, Tan L, Wang HF, Ma J, Liu J, Tan MS, Sun JH, Zhu XC, Jiang T, Yu JT: Serum Iron, Zinc, and Copper Levels in Patients with Alzheimer's Disease: A Replication Study and Meta-Analyses.J Alzheimers Dis 2015, 47:565-581.
8. Ventriglia M, Brewer GJ, Simonelli I, Mariani S, Siotto M, Bucossi S, Squitti R: Zinc in Alzheimer's Disease: A Meta-Analysis of Serum, Plasma, and Cerebrospinal Fluid Studies.J Alzheimers Dis 2015, 46:75-87.
9. Markiewicz-Zukowska R, Gutowska A, Borawska MH: Serum zinc concentrations correlate with mental and physical status of nursing home residents.PLoS One 2015, 10:e0117257.
10. James SA, Churches QI, de Jonge MD, Birchall IE, Streltsov V, McColl G, Adlard PA, Hare DJ: Iron, Copper, and Zinc Concentration in Abeta Plaques in the APP/PS1 Mouse Model of Alzheimer's Disease Correlates with Metal Levels in the Surrounding Neuropil.ACS Chem Neurosci 2017, 8:629-637.
11. Wang CY, Wang T, Zheng W, Zhao BL, Danscher G, Chen YH, Wang ZY: Zinc overload enhances APP cleavage and Abeta deposition in the Alzheimer mouse brain.PLoS One 2010, 5:e15349.
12. Tully CL, Snowdon DA, Markesbery WR: Serum zinc, senile plaques, and neurofibrillary tangles: findings from the Nun Study.Neuroreport 1995, 6:2105-2108.
13. Byun MS, Yi D, Lee JH, Choe YM, Sohn BK, Lee JY, Choi HJ, Baek H, Kim YK, Lee YS, et al: Korean Brain Aging Study for the Early Diagnosis and Prediction of Alzheimer's Disease: Methodology and Baseline Sample Characteristics.Psychiatry Investig 2017, 14:851-863.
14. Morris JC: The Clinical Dementia Rating (CDR): current version and scoring rules.Neurology 1993, 43:2412-2414.
15. Morris JC, Heyman A, Mohs RC, Hughes JP, van Belle G, Fillenbaum G, Mellits ED, Clark C: The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer's disease.Neurology 1989, 39:1159-1165.
16. Lee JH, Lee KU, Lee DY, Kim KW, Jhoo JH, Kim JH, Lee KH, Kim SY, Han SH, Woo JI: Development of the Korean version of the Consortium to Establish a Registry for Alzheimer's Disease Assessment Packet (CERAD-K): clinical and neuropsychological assessment batteries.J Gerontol B Psychol Sci Soc Sci 2002, 57:P47-53.
17. Lee DY, Lee KU, Lee JH, Kim KW, Jhoo JH, Kim SY, Yoon JC, Woo SI, Ha J, Woo JI: A normative study of the CERAD neuropsychological assessment battery in the Korean elderly.J Int Neuropsychol Soc 2004, 10:72-81.
18. DeCarli C, Mungas D, Harvey D, Reed B, Weiner M, Chui H, Jagust W: Memory impairment, but not cerebrovascular disease, predicts progression of MCI to dementia.Neurology 2004, 63:220-227.
19. Yesavage JA, Brink TL, Rose TL, Lum O, Huang V, Adey M, Leirer VO: Development and validation of a geriatric depression screening scale: a preliminary report.J Psychiatr Res 1982, 17:37-49.
20. Kim JY, Park JH, Lee JJ, Huh Y, Lee SB, Han SK, Choi SW, Lee DY, Kim KW, Woo JI: Standardization of the korean version of the geriatric depression scale: reliability, validity, and factor structure.Psychiatry Investig 2008, 5:232-238.
21. Armstrong C, Leong W, Lees GJ: Comparative effects of metal chelating agents on the neuronal cytotoxicity induced by copper (Cu+2), iron (Fe+3) and zinc in the hippocampus.Brain Res 2001, 892:51-62.
22. Wenham PR, Price WH, Blandell G: Apolipoprotein E genotyping by one-stage PCR.Lancet 1991, 337:1158-1159.
23. Park JC, Han SH, Yi D, Byun MS, Lee JH, Jang S, Ko K, Jeon SY, Lee YS, Kim YK, et al: Plasma tau/amyloid-beta1-42 ratio predicts brain tau deposition and neurodegeneration in Alzheimer's disease.Brain 2019, 142:771-786.
24. Reiman EM, Chen K, Liu X, Bandy D, Yu M, Lee W, Ayutyanont N, Keppler J, Reeder SA, Langbaum JB, et al: Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease.Proc Natl Acad Sci U S A 2009, 106:6820-6825.
25. Choe YM, Sohn BK, Choi HJ, Byun MS, Seo EH, Han JY, Kim YK, Yoon EJ, Lee JM, Park J, et al: Association of homocysteine with hippocampal volume independent of cerebral amyloid and vascular burden.Neurobiol Aging 2014, 35:1519-1525.
26. Jack CR, Jr., Wiste HJ, Weigand SD, Therneau TM, Lowe VJ, Knopman DS, Gunter JL, Senjem ML, Jones DT, Kantarci K, et al: Defining imaging biomarker cut points for brain aging and Alzheimer's disease.Alzheimers Dement 2017, 13:205-216.
27. Jack CR, Jr., Wiste HJ, Weigand SD, Rocca WA, Knopman DS, Mielke MM, Lowe VJ, Senjem ML, Gunter JL, Preboske GM, et al: Age-specific population frequencies of cerebral beta-amyloidosis and neurodegeneration among people with normal cognitive function aged 50-89 years: a cross-sectional study.Lancet Neurol 2014, 13:997-1005.
28. Tsai JZ, Peng SJ, Chen YW, Wang KW, Li CH, Wang JY, Chen CJ, Lin HJ, Smith EE, Wu HK, et al: Automated segmentation and quantification of white matter hyperintensities in acute ischemic stroke patients with cerebral infarction.PLoS One 2014, 9:e104011.
29. Yokokawa H, Fukuda H, Saita M, Miyagami T, Takahashi Y, Hisaoka T, Naito T: Serum zinc concentrations and characteristics of zinc deficiency/marginal deficiency among Japanese subjects.J Gen Fam Med 2020, 21:248-255.
30. Kuzuya M, Kanda S, Koike T, Suzuki Y, Satake S, Iguchi A: Evaluation of Mini-Nutritional Assessment for Japanese frail elderly.Nutrition 2005, 21:498-503.
31. Omran ML, Morley JE: Assessment of protein energy malnutrition in older persons, Part II: Laboratory evaluation.Nutrition 2000, 16:131-140.
32. Oh SB, Kim JA, Park S, Lee JY: Associative Interactions among Zinc, Apolipoprotein E, and Amyloid-beta in the Amyloid Pathology.Int J Mol Sci 2020, 21.
33. Wisniewski T, Castano EM, Golabek A, Vogel T, Frangione B: Acceleration of Alzheimer's fibril formation by apolipoprotein E in vitro.Am J Pathol 1994, 145:1030-1035.
34. Sanan DA, Weisgraber KH, Russell SJ, Mahley RW, Huang D, Saunders A, Schmechel D, Wisniewski T, Frangione B, Roses AD, et al.: Apolipoprotein E associates with beta amyloid peptide of Alzheimer's disease to form novel monofibrils. Isoform apoE4 associates more efficiently than apoE3.J Clin Invest 1994, 94:860-869.
35. Borden KL: RING fingers and B-boxes: zinc-binding protein-protein interaction domains.Biochem Cell Biol 1998, 76:351-358.
36. Klug A, Schwabe JW: Protein motifs 5. Zinc fingers.FASEB J 1995, 9:597-604.
37. Moir RD, Atwood CS, Romano DM, Laurans MH, Huang X, Bush AI, Smith JD, Tanzi RE: Differential effects of apolipoprotein E isoforms on metal-induced aggregation of A beta using physiological concentrations.Biochemistry 1999, 38:4595-4603.
38. Capasso M, Jeng JM, Malavolta M, Mocchegiani E, Sensi SL: Zinc dyshomeostasis: a key modulator of neuronal injury.J Alzheimers Dis 2005, 8:93-108; discussion 209-115.
39. Kato T, Inui Y, Nakamura A, Ito K: Brain fluorodeoxyglucose (FDG) PET in dementia.Ageing Res Rev 2016, 30:73-84.
40. Delvenne V, Lotstra F, Goldman S, Biver F, De Maertelaer V, Appelboom-Fondu J, Schoutens A, Bidaut LM, Luxen A, Mendelwicz J: Brain hypometabolism of glucose in anorexia nervosa: a PET scan study.Biol Psychiatry 1995, 37:161-169.